Notícias

By Karen Roman Inventiva S.A. (Nasdaq: IVA) said it designated Chris Benecchi as Chief Operating Officer, having previously served as Chief Executive Officer of Motric Bio (an Aditum Bio company). Mr. Benecchi will lead the company’s operational side as Inventiva comes close to its NATiV3 Phase 3 study results of lanifibranor in MASH, expected for […] The post Chris Benecchi Named Inventiva’s New Chief Operating Officer appeared first on ExecEdge.

Hardly for the first time recently, the company is making a pricey acquisition.

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index decreasing 0.5% a

Eli Lilly announced a $2.88 billion acquisition of Merida Biosciences. Here’s what it means for LLY shares.

OpenAI just built an AI-designed chip that already beats Nvidia's best in early tests, and one macro investor has pinpointed exactly when Nvidia's most valuable competitive advantage disappears entirely.

XLV bundles the entire healthcare sector into one tidy package, but its cap-weighted structure quietly siphons off the income that dividend investors came for. Three stocks already inside the fund tell a very different yield story.

In an interview with CNBC, CEO David Ricks said the company’s long-term strategy includes making its obesity franchise more durable and investing in technologies to transform the treatment of other diseases.

(Updates with index/price moves, macroeconomic data, and company/geopolitical news from the first pa

Eli Lilly stock has delivered very strong gains over the past five years. Current checks give a mixed read on valuation, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside, while market based multiples look closer to fair. Eli Lilly has returned 373.6% over five years, which puts a lot of optimism into the share price and raises the bar for what counts as good value today. The expanded use of drugs like Mounjaro and Zepbound in metabolic and cardiovascular care...

Eli Lilly Stock Slides as Pharma Giant Strikes $2.9 Billion Merida Deal

All three major US stock indexes were down in late-morning trading Monday, after Fox News reported t

The Merida acquisition adds an early-stage autoimmune platform as Lilly broadens its pipeline.

Eli Lilly and Co (NYSE:LLY) said on Monday it will acquire privately held Merida Biosciences for up to $2.88 billion in cash, part of a deal-making push to broaden its treatments for immune-related and allergic diseases. The acquisition continues a run of dealmaking for Lilly, whose deal...

Eli Lilly (LLY) has agreed to acquire Merida Biosciences for up to $2.875 billion in cash, as it see

Jim Cramer thought Caterpillar gave a viewer's portfolio real diversification until he looked closer and realized one quiet shift in the company's business had turned it into something else entirely.

Eli Lilly's Mounjaro wins FDA approval to reduce cardiovascular risk in high-risk T2D patients, expanding its use and commercial opportunity.

NVO's CagriSema is under U.S. regulatory review for obesity, with continued clinical progression to expand use amid increasing competition from LLY.

Lilly also announced that combining its inflammation treatment Taltz with Zepbound delivered lasting improvements in adults with psoriasis or psoriatic arthritis who were obese in two late trials.

The deal adds a pipeline targeting the antibodies behind Graves' disease, thyroid eye disease, food allergy, and other conditions

Eli Lilly has agreed to pay up to $2.875 billion in cash for biotechnology company Merida Biosciences in a deal that bolsters the drugmaker’s immunology portfolio.

Eli Lilly has agreed to pay up to $2.875 billion in cash for biotechnology company Merida Biosciences in a deal that bolsters the drugmaker’s immunology portfolio.

Eli Lilly agrees to acquire Merida Biosciences, the developer of autoimmune drugs, marking the latest move to bolster its portfolio through strategic acquisitions.

After two notable failures, the social anxiety R&D space gained a major player when Eli Lilly agreed to acquire AtaiBeckley this year.

The stock still presents a compelling case for investors, provided the clinical trial data can back up the early promise in its lead drug candidate.

Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.

Eli Lilly (NYSE: LLY) received FDA approval for Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. The decision expands Mounjaro’s use beyond blood sugar control to include reduction of cardiovascular events in at-risk patients. Mounjaro is the first dual GIP and GLP-1 receptor agonist to gain this cardiovascular risk reduction indication. The approval increases Eli Lilly’s addressable patient pool and affects its competitive position in diabetes and...

Eli Lilly is the leader in the GLP-1 space, but the company can't rest on its laurels.

Novo Nordisk is leaning into convenience as it tries to regain its lead in the GLP-1 weight-loss space.

Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.

Johnson & Johnson has outpaced the consumer staples sector over the past year, while analysts remain moderately bullish on the stock’s prospects.